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Abstract
 
The chronic graft-versus-host (cGVH) reaction results in a syndrome that closely resembles sys-
 
temic lupus erythematosus (SLE). It is induced in nonautoimmune mice by the transfer of allore-
active T cells. The availability of anti-DNA transgenes allows us to study the genetic origins of
autoantibodies in this model. We induced cGVH in two anti-DNA H chain site-directed
transgenic mouse strains. This resulted in clonal expansion and selection of specific mutations
in the anti–double-stranded (ds) DNA B cell population. These data, together with a high fre-
quency of anti-dsDNA B cell clones recovered as hybridomas, suggested that anti-dsDNAs are
the product of an antigen-driven immune response. Genetic analysis associated this response
with the generation of anti-dsDNA B cells through secondary rearrangements that replaced the
site-directed transgene (sd-tg) with endogenous VH genes.
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Introduction
 
SLE is an autoimmune disease characterized by lesions in
multiple organs and formation of autoantibodies. Among
 
these, anti–double-stranded (ds)
 
*
 
 DNA Abs are particularly
specific. Their rising titers can correlate with disease activ-
ity, and they are implicated in kidney pathology (1). Thus,
understanding what causes their production in SLE should
provide insight into the basic pathogenic mechanisms of
the disease itself. Previous studies on anti-DNA B cells
have demonstrated that in nonautoimmune mice these cells
are actively regulated (2–8). How tolerance loss occurs in
SLE is not yet clear.
The chronic graft-versus-host (cGVH) model of SLE is
produced by the transfer of allogeneic T cells into normal
mice. Donor helper T cells react against incompatible host
class II structures and generate T help. This T help then ac-
tivates the self-reactive host B cells that produce the au-
toantibodies characteristic of SLE (9–17). In our experi-
ments cGVH is induced by the transfer of alloreactive
spleen cells from “nonautoimmune” bm12 mice into
coisogenic, “nonautoimmune” C57BL/6 (B6) recipients
 
(bm12
 
→
 
B6). As donor and recipient cells differ by only
three amino acids on their class II molecule, this difference
in the MHC can be identified as the factor responsible for
the cGVH reaction (9–11).
We induced cGVH in B6 mice carrying two different H
chain Ig site-directed transgenes (sd-tg), the 3H9 knock-in
(KI; reference 6), and the 3H9/56R.KI (18), which possess
an increased frequency of anti-DNA B cells. Previous stud-
ies have shown that the 3H9 H chain plays a key role in
determining DNA specificity. When paired with most but
not all L chains, it gives rise to either anti-single stranded
(ss) DNA or anti-dsDNA Abs (19). Thus, these 3H9.KI
mice enabled us to focus on the particular anti-dsDNA B
cell population transitioning from tolerance to autoimmu-
nity, and to do so in the context of a broad repertoire. The
3H9/56R sd-tg has an additional arginine in the CDR2 of
the 3H9 H chain, which heightens its affinity for dsDNA
(18) and generates a more restricted repertoire. Here, with
few exceptions, the pairing of L chains with the 3H9/56R
H chain gives rise to anti-dsDNA Abs (5, 18). Affinity of
the B cell receptor for self-Ag could help determine the se-
lective breakdown of tolerance in SLE. Thus, by compar-
ing these site-directed transgenic models, we were able to
determine how both the restricted repertoire and the in-
creased dsDNA affinity affects tolerance.
Our data indicate that the mechanisms of tolerance
loss appear to be similar in both mouse models, al-
though the resultant phenotype is more pronounced in the
cGVH.3H9/56R mice. We found that the allo-T help of
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versus-host; ds, double-stranded; FWR, framework; KI, knock in; sd-tg,
site-directed transgene; ss, single-stranded; tg, transgene. T
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Heavy Chain Rearrangement in Anti–double-stranded DNA B Cells
 
cGVH induces two stages of activation: a nonspecific stage
that affects most splenic B cells (20), and an Ag-specific
stage associated with the production of SLE-Abs. This
latter, receptor-driven stage is specifically marked by oli-
goclonal B cell expansion, a high frequency of mutations
and a high degree of selection, both positive and nega-
tive, on the anti-dsDNA B cell population. Most impor-
tantly, however, genetic analysis associated these re-
sponses with the generation of anti-dsDNA B cells
through secondary rearrangements.
 
Materials and Methods
 
Mice
 
The generation of 3H9 KI and 3H9/56R.KI (or site-directed
transgenic) mice has been described previously (6, 18). The sd-tg
has been backcrossed onto the nonautoimmune B6 background
for at least seven generations (unless otherwise stated) to engender
3H9.KI.B6 (3H9(
 
 
 
)) or 3H9/56R.KI.B6 (56R(
 
 
 
)). The pres-
ence of the 3H9 or 3H9/56R sd-tg was determined by PCR am-
plification of tail DNA (3).
B6 and coisogenic B6.C-H2
 
bm12
 
/KhEg (bm12) mice were
originally obtained from The Jackson Laboratory. Strains B6 and
bm12 differ only by three amino acids in the 
 
 
 
-chain of the I-A
molecule.
All mice were bred and maintained in our mouse colony at the
University of Pennsylvania Medical Center.
 
Experimental cGVH Disease Protocol
 
Mice were 2 to 5 mo at the time of cGVH initiation. In all
cases, age-matched B6 mice or 3H9/56R.KI negative littermates
(56R(
 
 
 
)) were used as controls. cGVH disease was induced as
described previously (9). Briefly, recipient mice on a B6 back-
ground were injected intraperitoneally with single cell suspen-
sions of 10
 
8
 
 class II incompatible bm12 donor splenocytes, pre-
pared by pressing donor spleens through a wire mesh screen in
HBSS.
 
Characterization of the Autoimmune Disease
 
Follow-up of Mice.
 
Blood samples were obtained from experi-
mental mice before the induction of cGVH disease and at 2- to
4-wk intervals thereafter. Sera were stored at –20
 
 
 
C for later
analysis.
 
Detection of Autoantibodies in Sera ELISA.
 
Expression of anti-
DNA Abs was determined via a solid-phase ELISA in assays sim-
ilar to those described previously (21, 22). Plates were coated
with optimal concentrations of autoantigen, and sera were added
at 1:500 dilution. Biotinylated goat anti–mouse IgG (pFc’ spe-
cific; Jackson ImmunoResearch Laboratories) was added as a sec-
ondary Ab. The following autoantigens were used: (a) ssDNA:
calf thymus DNA (Sigma-Aldrich) was heated to 97
 
 
 
C for 10
min and cooled on ice quickly. (b) dsDNA:calf thymus DNA
was extracted with chloroform, precipitated by addition of etha-
nol, and then treated with S1 nuclease for 45 min at 37
 
 
 
C, to re-
move ss regions.
For the ELISA for dsDNA, plates were first coated with poly-
 
l
 
-lysine, followed by an incubation with the purified calf thymus.
Before the usual BSA/Tween blocking step, a preblock with
poly-
 
l
 
-glutamine was performed.
 
For reference, a standard serum from a diseased MRL
 
/lpr
 
mouse with high titer of autoantibodies was tested at serial two-
fold dilutions from 1:250 to 1:128,000.
 
Allotype-specific Anti-dsDNA.
 
The allotypes of IgG2a anti-
dsDNA Abs were tested by assays similar to those for anti-ds-
DNA, except that the sera were diluted 1/250. The assays were
developed with rabbit anti–mouse preabsorbed allotype reagents
(anti-IgG2a
 
a
 
 or anti-IgG2a
 
b
 
; Nordic Immunology) and detected
with alkaline phosphate anti–rabbit IgG Ab (Jackson Immu-
noResearch Laboratories).
 
Generation of Hybridomas
 
To induce cGVH, a 3H9.KI and a 3H9/56R.KI mouse (back-
crossed three times onto the B6 background) were injected with
bm12 spleens as described above. The presence of anti-DNA Abs
in sera was corroborated 10-wk-postinjection, and hybridomas
from the cGVH mouse were generated as described (5). In brief,
spleen cells from the immunized mice were fused without further
manipulation to Sp2/0 myeloma. All hybridomas were plated at
limiting dilution, and wells bearing single colonies on 96-well
plates were expanded for further analysis.
 
ELISA Assays on Hybridomas
 
Ig Secretion in Supernatants.
 
Isotype and Ig concentration in
culture supernatants were determined using a solid phase ELISA
assays, as described (23). In brief, to determine the isotype, plates
were coated with optimal concentrations of unconjugated anti-
total Ig, and serial dilutions of supernatants from individual hy-
brids were added. Binding was detected through further incuba-
tion with anti-IgM, or anti-IgG coupled to alkaline phosphatase
and developed with alkaline phosphatase substrate. Ig concentra-
tion was determined by comparing samples to a standard curve
generated by a titrated isotype-matched Ab.
 
DNA Binding.
 
Binding to dsDNA was measured by a two
step fluid-phase ELISA, as described previously (2, 24). The Ab
concentration was normalized for each individual sample. Appro-
priate concentrations of Ab and biotinylated dsDNA were mixed,
incubated, and transferred to avidin-coated microtiter plates.
Bound DNA-Ab complexes were detected with alkaline phos-
phatase-conjugated anti–mouse isotype-specific Ab.
 
Allotype-specific Anti-dsDNA.
 
The allotypes of IgG2a anti-
dsDNA monoclonal Abs were tested by assays similar to those for
allotype-specific anti-dsDNA in sera, except that in this case hy-
bridoma supernatants were added.
 
PCR Assays on Hybridoma DNA
 
Genomic DNA was purified from individual hybrids. 100 ng of
DNA were used in each reaction. Primers and conditions for H
and L chain PCR assays have been detailed previously (6, 23, 25).
 
H Chain PCR Assay.
 
The presence of 3H9 or 3H9/56R H
chain sd-tg was identified by PCR amplification using primers
complementary to the 3H9 H chain leader exon (the LD3H9)
and the CDR3 sequence (3).
 
 
 
 L Chain PCR Assay.
 
For the J
 
 
 
 typing PCR assays, Vs
(Schlissel; reference 26) or L5 forward V
 
 
 
 primers were used with
J
 
 
 
2, or J
 
 
 
5 reverse-J
 
 
 
 primers (27). The Vs PCR primer should
amplify 80–90% of V
 
 
 
 genes. The size of the PCR product cor-
responds to the J
 
 
 
 segment participating in the rearrangement
event and has been described previously (25).
 
 
 
 L Chain PCR Assays.
 
The PCR conditions for detecting
rearrangement of the 
 
 
 
 genes, 
 
 
 
1 and 
 
 
 
x, were performed as de-
scribed previously (23).T
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V
 
 
 
38c and V
 
 
 
32a.
 
To detect J
 
 
 
 usage of the editor rearrange-
ments, V
 
 
 
-specific forward primers (V
 
 
 
38c and V
 
 
 
32a) were used
in combination with the standard reverse primers (J
 
 
 
2, J
 
 
 
5). The
primers and conditions have been described previously (18).
 
Sequence Analysis of H Chain Genomic DNA
 
The H chain V regions were sequenced from DNA according
to protocols described (28). In brief, DNA was isolated and am-
plified using constant region-specific primers. The PCR product
was gel purified and sequenced using an automated sequence
analyser (ABI). The 5
 
 
 
 primers used were the LD3H9, that binds
V genes with leader sequences similar to those used by the 3H9
sd-tg, in combination with a primer located in the J
 
H
 
-C
 
H
 
 intron.
This PCR is not as specific as the LD/CDR3 PCR and detects
3H9 or 3H9/56R-sd-tgs with mutations in CDR3 region, as
well as V
 
H
 
 replacements where the invading V
 
H
 
 gene uses a 3H9-
like leader sequence (which includes all members of the J558
family, that correspond to 80% of all VH genes).
 
Statistics
 
Statistical significance was determined using chi-square for hy-
bridoma analysis; and 
 
t
 
 test for analysis of ELISAs.
 
Online Supplemental Material
 
L chain rearrangement of the clones is presented in online sup-
plemental Tables S1 to S3. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20020737/DC1.
 
Results
 
Our previous work began to define the mechanisms by
which the allo-T-help of cGVH provokes a loss of tolerance
in mice carrying the anti-DNA H chain sd-tg, 3H9.KI (20).
To determine whether this process is affected by the use of a
different anti-DNA H chain, we induced cGVH in mice
carrying a related sd-tg, the 3H9/56R.KI. This sd-tg differs
from the 3H9 by a single mutation that substitutes an argi-
nine for a histidine at position 56 in the CDR2 region. This
results in higher affinity for dsDNA, a more restricted reper-
toire of L chains capable of vetoing DNA binding, and an
 
increased frequency of VH replacement (5, 18). In this paper
we compare the results obtained from inducing cGVH in
3H9/56R.KI on a B6 background to those obtained from
inducing cGVH in 3H9.KI mice on the same background.
The experimental group consisted of unirradiated 3H9/
56R.KI recipients injected with bm12 spleen cells from
mice of the same sex (bm12
 
→
 
56R(
 
 
 
)). Negative control
groups consisted of 3H9/56R.KI mice and 3H9/56R neg-
ative littermates that had received syngeneic B6 spleen cells
(B6
 
→
 
56R(
 
 
 
) and B6
 
→
 
56R(
 
 
 
), respectively). 3H9/56R
negative littermates and normal B6 mice that had received
bm12 spleen cells (bm12
 
→
 
56R(
 
 
 
) and bm12
 
→
 
B6, respec-
tively) were also included as a comparison group.
 
Induction of Anti-DNA after cGVH.
 
All mice undergo-
ing cGVH were bled monthly, and the sera tested by
ELISA for the presence of anti-ssDNA and anti-dsDNA
IgG Abs. The 3H9/56R.KI.B6 mice (56R(
 
 
 
)) produced
both anti-ssDNA and anti-dsDNA IgGs, even before the
transfer of bm12 cells (Fig. 1). This was unexpected, as
BALB/c mice carrying a conventional 3H9/56R trans-
gene did not produce anti-DNA Abs (5), and 3H9/
56R.KI.BALB/c mice produce only modest amounts of
IgM anti-dsDNA (unpublished data). Thus, the spontane-
ous breakdown in tolerance to DNA was influenced by the
background genes of the mice, the placement of the trans-
gene (tg) in the genome, and the affinity of the Ig H chain.
After cGVH induction, higher levels of both anti-
ssDNA (P 
 
  
 
0.05) and anti-dsDNA (P 
 
  
 
0.05) Abs were
found in 3H9/56R.KI mice (compare 56R(
 
 
 
) vs.
bm12
 
→
 
56R(
 
 
 
)). Thus, allogeneic T cell help increased
anti-DNA Abs in 3H9/56R.KI mice (Fig. 1).
In bm12
 
→
 
56R(
 
 
 
) mice, anti-ssDNA IgGs peaked at
a time and at levels similar to those in our nontrans-
genic  cGVH groups (bm12
 
→
 
56R(
 
 
 
), P 
 
  
 
0.05; and
bm12
 
→
 
B6, P 
 
  
 
0.05; unpublished data). By contrast, anti-
dsDNA IgGs peaked by 4 wk and at levels much higher
than those found in nontransgenic cGVH (P 
 
  
 
0.05) and
bm12
 
→
 
3H9(
 
 
 
) mice (P 
 
  
 
0.05; unpublished data). As in
Figure 1. Anti-DNA Abs in
3H9/56R.KI mice after cGVH.
Groups tested: n   4–5 mice per
group. Experimental GVH
group: bm12 spleen cells injected
into 3H9/56R.KI recipients
(bm12→56R( ),   ). Positive
GVH control: bm12 spleen cells
injected into 3H9/56R.KI nega-
tive littermates (bm12→56R( ),
gray triangle). Negative con-
trols: syngeneic B6 spleen cells
injected into 3H9/56R.KI posi-
tive mice (B6→56R( ),   );
B6 spleen cells injected into
3H9/56R.KI  negative litter-
mates (B6→56R( ),   ). Mice
were bled at 4-wk intervals. The presence of anti-DNA Abs in sera was tested by ELISA. Results represent means   SEM. (A) anti-ssDNA IgG. (B) anti-
dsDNA IgG. Titers of anti-dsDNA in bm12→56R( ) differed from the positive control bm12→56R( ) at all weeks (P   0.05), while for anti-ssDNA,
the difference was only at the prebleed. Titers of both anti-ssDNA and anti-dsDNA from B6→56R( ) mice differed significantly from those of
B6→56R( ) mice at all time points. Anti-dsDNA titers from bm12→56R( ) were significantly higher than those from 3H9( ) at 4 and 8 wk after
cGVH (P   0.05) (unpublished data). MRL/lpr sera tested at the same concentration gave an OD of 0.9 for anti-dsDNA. * represents statistical difference
(P   0.05) from the appropriate negative control.T
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30 Heavy Chain Rearrangement in Anti–double-stranded DNA B Cells
3H9.KI after cGVH, this difference in response between
anti-ssDNA and anti-dsDNA suggests that the presence of
the anti-DNA Ig sd-tg focused allogeneic T cell help on
anti-dsDNA B cells (20; see Fig. 1).
Comparison of Hybridomas and mAbs from 3H9.KI and
3H9/56R.KI Mice after cGVH. To study the nature of
autoantibodies in more detail, we compared a hybridoma
panel from a bm12→3H9( ) mouse to one from a
bm12→56R( ) mouse. Both panels were generated 10 wk
after cGVH was induced, a time when anti-dsDNA titers
were still high.
Results from the bm12→3H9( ) and bm12→56R( )
hybridomas support the conclusion that B cells from mice
undergoing cGVH were activated in vivo. We observed a
consistently high percentage ( 70%) of hybridomas that
were anti-dsDNA  (see anti-dsDNA  group; Table I). As
most anti-dsDNA  clones in the bm12→56R( ) set
were not using the 3H9/56R sd-tg (see below), this fre-
quency cannot be directly attributed to the presence of
our anti-DNA H chain. Rather, the high frequency of
anti-dsDNAs suggests that the self-Ag(s) involved was se-
lectively activating these cells in vivo. It is in fact possible
that the initial 56R B cells acted as APCs, presenting
DNA associated molecules and therefore stimulating
more anti-DNA B cells to mount a response. Also, iso-
type usage in the hybridomas indicated Ag activation:
42% of anti-dsDNA  clones from the bm12→3H9( )
mouse, and 68% of those from the bm12→56R( ) se-
creted IgG. This activation may explain why hybridomas
were formed without in vitro stimulation. These results
provide strong evidence for activation by endogenous
self-Ag(s).
Ig H Chain Gene Usage in cGVH Mice: Loss of the sd-tg.
To determine the contribution of the sd-tg to the anti-
dsDNA specificity in cGVH, we analyzed the rearranged Ig
genes in our hybridoma panels. We first assessed the status
of the 3H9 and 3H9/56R construct by PCR. The test used
primers complementary to the 3H9 and 3H9/56R H chain
leader, and to the CDR3 sequence specific for the sd-tg.
Successful amplification by these primers indicated the
presence of the complete sd-tg.
DNA sequence analyses further confirmed the presence
of this unmodified sd-tg in all PCR positive bands for both
3H9 and 3H9/56R (unpublished data). On this basis, we
defined those hybridomas that had retained the sd-tg as tg
positive (3H9tg  and 56Rtg ; Table I).
By contrast, we defined a tg  B cell (3H9tg  or 56Rtg ;
Table I) as one whose DNA had failed to amplify the 3H9
VH with primers complementary to the 3H9 CDR3 and
leader (LD). There are several ways that a tg  B cell might
arise. One is mutation in CDR3 that destroys complemen-
tarity between the 3H9VH and the CDR3 PCR primer.
We have ruled out this case by showing that the tg  hy-
bridomas also failed to amplify with the LD-JHCH primer
combination (unpublished data). JHCH binds to a site be-
tween JH4 and CH (28). tg  B cells might arise by replace-
ment of 3H9VH by a VH (with a different LD sequence)
or DH invasion of 3H9VH (in which case there is no ac-
companying LD sequence). Both examples have been de-
scribed (6). In addition, there are trivial ways of generating
a tg  such as segregation of the tg  bearing chromosome
after fusion. To test for loss of the locus we amplified hy-
bridoma DNA with a 3H9 CDR3-reverse primer (the
complement of the 3H9 CDR3 primer described above)
and the JHCH primer. This primer should amplify trun-
cated or replaced 3H9VH genes because both occur at the
embedded heptamer 5  of CDR3. About 2/3 of VH and
DH replacement is usually at a site just 5  of CDR3 and
such cases are amplified by this primer combination (un-
published data), the rest of replacements nibble into CDR3
Table I. Comparison of dsDNA Binding and H Chain Usage in 3H9.KI and 3H9/56R.KI Hybridomas after cGVH Induction
bm12→3H9( ) bm12→56R( )
Total 3H9tg a 3H9tg  Total 56Rtg  56Rtg 
DNA bindingb
dsDNA  26 (68%) 17 (65%) 9 (35%) 56 (72%) 16 (29%) 40 (71%)
dsDNA  12 (31%) 3 (25%) 9 (75%) 22 (28%) 2 (9%) 20 (91%)
Isotypec
IgM 20 (53%) 12 (60%) 8 (44%) 22 (28%) 18 (100%) 4 (7%)
IgG 18 (47%) 8 (40%) 10 (55%) 56 (72%) 0 56 (93%)
Total 20 (53%) 18 (47%) 18 (23%) 60 (77%)
Monoclonal hybridomas were derived from unmanipulated spleen cells from either 3H9.KI or 3H9/56R.KI mice 10 wk after cGVH induction. Ig-
secreting hybridomas were assayed for dsDNA binding, Ig isotype, and persistence of the H chain sd-tg (3H9 or 3H9/56R). Some of the 3H9.KI
results have already been published (reference 20).
aRetention of the 3H9 or 3H9/56R H chain sd-tg was determined by specific PCR assays. Positive clones are grouped in the column under
3H9tg  or 56Rtg . Negative clones, with disrupted sd-tgs, are grouped in the column under 3H9tg  or 56Rtg .
bdsDNA binding was determined by a fluid phase ELISA, and confirmed by either a solid phase ELISA or crithidia assay.
cIg isotype was assessed with a solid phase ELISA.T
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31 Sekiguchi et al.
and are unlikely to be amplified. We tested 30 tg  hybrid-
omas by this PCR and found that 18 gave a PCR product.
Thus, we believe that the tg  category in Table I is mainly
the result of 3H9VH truncation or VH replacement.
The dominant role of the 3H9 H chain in DNA bind-
ing (24) was evident in the anti-dsDNA  clones in
bm12→3H9( ), where most anti-dsDNA mAbs used the
3H9 sd-tg. Nevertheless, in the same fusion, 35% of the
anti-dsDNA  cells actually lost the 3H9 sd-tg. This ten-
dency was even more marked in the bm12→56R( ) fu-
sion, where the majority (72%) of anti-dsDNA  clones did
not use the sd-tg. Strikingly, of the anti-dsDNA IgG
clones, 19% from bm12→3H9( ), and 100% of those de-
rived from bm12→56R( ) were tg . This suggests that
isotype switching (or the stage of Ag driven activation) can
be linked with the disruption of the sd-tg under cGVH.
Sd-tg Replacement in bm12→3H9( ) and bm12→56R( )
Mice. The sd-tg can be replaced by another V region from
the same chromosome (VH replacement; reference 6), or
the other allele can be rearranged after sd-tg inactivation.
We were able to determine which mechanism had been
used by defining the allotype of the B cell receptor: the
transgenic allele is of the a allotype, and the untargeted al-
lele is of the b allotype. Of the IgG anti-dsDNA 3H9tg 
hybridomas, 50% were IgG2ab. Of the anti-dsDNA IgG 
hybridomas from the bm12→56R( ), 79% expressed
IgG2ab, while only 5% used the IgG2aa from the 3H9/56R
transgenic allele (Table II). None of the 3H9/56R IgG
clones expressed the sd-tg itself. Therefore, in both fusions,
secondary rearrangements at the H chain took place in a
significant percentage of the population, resulting in the
expression of the untargeted allele.
This distribution of Igha and Ighb mAbs parallels serum
IgG expression. After cGVH induction, both 3H9.KI and
3H9/56R.KI mice produced anti-dsDNA Abs from both
the a (transgenic) and the b (nontransgenic) allele (Fig. 2).
The serum data from the 3H9/56R experiment provided
additional in vivo information: anti-dsDNA Abs in the
(pre-cGVH) 3H9/56R.KI.B6 mice were of the a-allele. As
this is the site-directed transgenic allele, it is likely that the
mechanism of central tolerance failed to eliminate B cells
carrying the 3H9/56R H chain (29). Significantly, how-
ever, anti-dsDNA Abs expressing the b (nontransgenic) al-
lele were produced only under cGVH.
H Chain Usage. To determine why the allotype
switched after cGVH, we analyzed VH usage. V region nu-
cleotide sequences were assigned to VH germlines by com-
parison to established sequences, from GenBank and from
Haines et al. (30). The latter offered a more complete de-
lineation of the b allotype of the B6 strain. Out of the 12
IgG2ab hybrids sequenced, 7 used the J558.B3 gene (acces-
sion no. AF296420), 2 the J558.B4 (AF296421), 1 the
MVARG2 and 2 the J558.B18 (AF296435). All 3 IgG2aa
(transgenic allele) hybrids used the 45.21.1 gene.
Table II. Allotype Analysis of IgG Hybridomas
IgG2aa IgG2ab Non-IgG2a
bm12→3H9( )
dsDNA a IgG   10
3H9tg    6 (60%) 4 (67%) 0 2 (33%)
3H9tg    4 (40%) 0 2 (50%) 2 (50%)
dsDNA  IgG   7
3H9tg    2 (29%) 0 0 2 (100%)
3H9tg    5 (71%) 0 0 5 (100%)
bm12→56R( )
dsDNA  IgG   38
56Rtg    0
56Rtg    38 (100%) 2 (5%) 30 (79%) 6 (16%)
dsDNA  IgG   18
56Rtg    0 (0%)
56Rtg    18 (100%) 1 (5%) 10 (55%) 7 (39%)
The use of the sd-tg allotype (a) or the non-sd-tg allotype (b) was
determined in supernatants of IgG2a hybridomas by ELISA. Clones that
were neither IgG2aa nor IgG2ab were presumably using another isotype.
aTransgene typing as in Table I.
Figure 2. Allotype analysis of IgG2a anti-dsDNA Abs in 3H9.KI and
3H9/56R.KI mice after cGVH. The use of the sd-tg (a) allotype (left
hand graphs) or the nonsd-tg (b) allotype (right hand graphs) in IgG2a
anti-dsDNA Abs was determined by ELISA in sera. (A) 3H9( ),  ,
and bm12→3H9( ), gray diamond, mice. (B) 56R( ),   , and
bm12→56R( ),  , mice.T
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Properties of the H Chain Used by Anti-dsDNA  Cells: Bi-
ased VH Usage. In the specific anti-dsDNA  response,
germline genes J558.B3, J558.B4, and 45.21.1, are over-
represented (see Fig. 3 and Table III). This over-represen-
tation can be explained in part by clonal expansion (see be-
low). Nevertheless, the representation of these genes is
higher than would be expected, and likely indicates a pro-
cess of Ag (DNA) selection. Indeed, these germline se-
quences do share a cluster of codons rich in asparagine res-
idues. Located at positions 39, 41, and 42 in the CDR2T
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region, these asparagines constitute a pocket of positive
charges that might strongly attract the negatively charged
dsDNA backbone. The presence of aspartate residues in
the CDR1 might neutralize the positive charge of this
CDR2 pocket; and such aspartates are present in other
germlines such as J558.B1 and J558.B2 from B6. How-
ever, germlines J558.B3 and J558.B4 lack such negatively
charged clusters in the CDR1. Therefore, J558.B3 and
J558.B4 are different from most other VH genes by the
combination of the concentrated area of positive charges in
the CDR2 and the lack of a strong negatively charged
pocket in the CDR1 region (30). Since, according to the
current database, these germlines are unique to B6 mice,
the VH.B6 allotype may be especially amenable for gener-
ating anti-dsDNA Abs.
Thus, CDR2 appears to be a major contributor to DNA
binding. Analysis of mutations supports this hypothesis be-
cause replacement to arginines occurred in several of the
codons in the nearby framework region (FWR 2). For ex-
ample, replacements to arginine are found between posi-
tions 25 and 30 of the FWR2 region in anti-DNA  hy-
brids such as nos. 155, 255, 127, 214, and 89. As stated
above, and shown in Fig. 3, the FWR2 and CDR2 regions
are close together in the H chain structure. The inserted
positive arginines occupy the space adjacent to the previ-
ously mentioned pocket of asparagines, and the mutations
to arginine may increase the tendency of this region to bind
dsDNA. This analysis suggests that the combination of in-
herited asparagine residues and mutations to arginine con-
tribute to DNA binding.
Clonal Relatedness. Clonal relatedness is shown by
identity or near identity of the CDR3s of the Ab (31). Ta-
ble III summarizes the genes used by each hybrid. Of the
12 IgG2ab hybridomas, six shared both the J558.B3 VH
gene and a CDR3 region consisting of 3 N nucleotides, a
D-D fusion (composed of an FL16.1 and a Q52 gene), and
Figure 3. Nucleotide and deduced amino acid sequences of hybridoma H chains from the bm12→56R( ) mouse after the induction of cGVH. The
panel shows nucleotide sequences of the H chains used by 56Rtg  hybridomas derived from the bm12→56R( ) mouse. The sequences for each hybrid
were determined by using the LD-JHCH PCR, as described in Materials and Methods. For each hybridoma, sequences were analyzed for homology to
published VH gene segments using both GenBank/EMBL/DDBJ databases and B6 VH gene segments determined by Haines et al. (reference 30). Estab-
lished germline codons and their corresponding single letter amino acids are shown in the top rows. Sequences from hybridomas using the same H chain are
grouped together below these codons. Hybridomas 153, 223, 216, 228, 135, and 155 represent potential members of the same clone. Hybridomas 127, 214,
and 107 represent potential members of a second clone. Clone assignments were made as described in Results. Dashes represent bases identical to those of
the germline. Upper case letters indicate replacement mutations; silent mutations are in lower case. The J558.B3, J558.B4, and J558.B18 sequences described
in this paper are available from GenBank/EMBL/DDBJ under the following accession nos.: AF296429, AF296421, AF296435, respectively. CDR, com-
plementarity-determining regions.
Table III. Summary of Sequence Characteristics of tg  Hybridomas for bm12→56R( ) Fusion
Cell Clone Isotype VHa DHb JH CD3 lengthc V a J d dsDNA binding
153 1 IgG2ab J558.B3 FL16.1/Q52 4 13 NF  
223 1 IgG2ab J558.B3 FL16.1/Q52 4 13 2  
216 1 IgG2ab J558.B3 FL16.1/Q52 4 13 2  
228 1 IgG2ab J558.B3 FL16.1/Q52 4 13 NF  
135 1 IgG2ab J558.B3 FL16.1/Q52 4 13 2  
155 1 IgG2ab J558.B3 FL16.1/Q52 4 13 2  
255 3 IgG2ab J558.B3 FL16.1/FL16.1E/Q52 4 13 2  
169 4 IgG2ab J558.B4 FL16.1/ST4-C 4 9 NF  
198 5 IgG2ab J558.B4 ST4/FL16.2-C 4 7 NF  
89 6 IgG2ab MVARG2 SP2.9/Q52 4 9 ae4 5  
177 7 IgG2ab J558.B18 ST4/FL16.1E/Q52-C 4 10 2  
2 8 IgG2ab J558.B18 ST4/FL16.1E/SPE.8 4 10 Vk38c-Jk2  
127 2 IgG2aa 45.21.1 FL16.1/ST4/FL16.1-C 4 13 bb1 4  
214 2 IgG2aa 45.21.1 FL16.1/ST4/FL16.1-C 4 13 bb1 4  
107 2 IgG2aa 45.21.1 FL16.1/ST4/FL16.1-C 4 13 bb1 4  
Hybrids were assigned to clones according to the criteria outlined in the text. Clone names are given for all hybrids.
aVH and V  assignments were made based on the closest sequence homology to known germline genes.
bDH designations were made by homology to the closest DH gene.
cThe CDR3 length is defined by the number of amino acids present between the last amino acid encoded by VH genes (the invariant arginine resi-
due), and the residue encoded by all JH genes at position 7.
dJ  genes are numbered 1–5 in the order 5  → 3 .T
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a JH4 segment. This makes it highly probable that these
clones were derived from the same in vivo founder,
the VHJ558.B3/DFL16.1/DQ52/JH4 clonotype (hereafter
clone 1). Similarly, the 3 IgG2aa hybrids shared the 45.21.1
VH gene, as well as a CDR3 region consisting of 4 N nu-
cleotides, a D FL16.1, a D ST4, an inverted D FL16.1 gene
and a JH4 segment (see also Fig. 4). Thus, in this mouse, B
cells with common, anti-dsDNA autoantibody specificities
provide evidence of clonal expansion. From these data, we
conclude that the six anti-dsDNA-producing hybridomas
derived from one B cell precursor (clone 1), and the three
IgG2aa hybrids from another (clone 2). Additional analysis
showed that the CDR3 regions are relatively long; in clone
1 and 2 the length is 13 amino acids. A high frequency of
D-D fusions and JH4 usage, as reported by Monestier, was
also seen. (32, 33).
High Frequency of Mutations in cGVH B Cells. By com-
paring these VH sequences to germline V, D and J se-
quences (reference 30, and GenBank), the presence and
frequency of somatic mutations could be determined (Figs.
3 and 4). In all VH regions of the IgG Abs sequenced, this
comparison revealed a high frequency of mutation, ranging
from 14 to 33 per sequence, with an average of 24. The
frequency of mutations in this cGVH model was more than
twice as high as that seen during secondary immune re-
sponse to foreign Ags (average lower than 10 mutations per
Ab; reference 34). It was also notably higher than in au-
toantibodies from the MRL/lpr mice (35). This high fre-
quency of mutations most likely reflects a lengthy period of
activation during cGVH, and suggests that hypermutation
and clonal expansion are essential to the generation of au-
toreactivity in this syndrome.
As expected, some mutations were shared among clonal
relatives. In clone 1, all hybrids shared a T to C substitution
in JH4, three shared one replacement mutation, while two
hybrids shared four other mutations. In clone 2, eleven
mutations were shared. The individual hybrids derived
from clone 1 differed from each other by 11 to 24 muta-
tions; in clone 2, 18.5 different mutations were found
among the two main branches of the clonal tree (Fig. 5).
These unique mutations suggested extensive expansion of
the clones late in the response.
L Chain Rearrangement in bm12→3H9( ) and bm12→
56R( ) Clones. To determine the contribution of L
chain editing to the self-reactive phenotype of these
cells, we assayed the rearrangement status of the   and  
genes in hybridomas from both mice, using a series of
PCR assays (online supplemental Tables S1–S3). As de-
scribed in our previous paper (20), both J 5 and  1 usage
was high in anti-dsDNA 3H9tg  hybridomas. As com-
pared with their usual frequency (36, 37), this increased
usage of downstream genes supports the idea that anti-
Figure 4. Nucleotide sequences of the recombinational junctions of hybridoma H chains from the bm12→56R( ) fusion. Hybridomas in this figure
are the same ones depicted in Fig. 3, and are presented in the same order. The top line of each group represents the presumed V, D, and J germline (GL)
genes used. Sequence identities with the germline VH or JH are denoted by dashes. The DH segments are indicated on the right. DH sequences are de-
termined by identifying at least 4 nucleotide identities to a known DH segment. These, as well as the original DH sequences, are indicated in parentheses.
The non-DH, non-VH sequences are assumed to be N sequences. As in Fig. 3, the VH sequences are assigned to the known VH germline from the
GenBank or Haines et al. (reference 30). Nucleotides that differ from germline are underlined.T
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dsDNA B cells have undergone secondary L chain rear-
rangements. In the present study we tested the same set of
clones for rearrangement to L chains that veto dsDNA
binding in the context of the 3H9 or 3H9/56R sd-tg
(V 38c, V 32a, and  x). Some clones indeed had rear-
ranged V 38c and V 32a, but they also appear to be
expressing another V  chain simultaneously (dual rear-
rangement is represented by a superscript a in online sup-
plemental Table S1).
Of the anti-dsDNA hybridomas from the 3H9/56R fu-
sion, 16 (30%) retained the H chain sd-tg. L chain data
from these hybridomas demonstrated a biased V  reper-
toire: 10 (62%) used V 38c (online supplemental Table
S2). A biased distribution of J  gene segments was also ob-
served among these 56Rtg  hybridomas: 5 (32%) arranged
to J 5, a frequency higher than that found in conventional
mice. Only one clone used both V 38c and J 5. All these
data point to secondary rearrangements of the L chains in
anti-dsDNA 56Rtg  hybridomas. It is intriguing that
V 38c, when paired with the 3H9/56R sd-tg, did not ap-
pear to veto dsDNA binding. This might be explained by
rearrangement of the other allele in three of the ten clones,
similar to what was seen in the 3H9 clones. Indeed, we
showed by sequence analysis that at least one of these sec-
ond L chains could be functional (unpublished data). In
five other clones, we observed triplet insertions and muta-
tions in the V 38c gene at its junction with the J  gene
(unpublished data). These mutations may have altered the
editing potential of the L chain.
Discussion
Mice undergoing cGVH develop a lupus disease similar
to mice with spontaneous lupus. cGVH mice develop the
same spectrum of autoantibodies and similar kidney pathol-
ogy. We have extended the comparison between these
models to include the genetic control and etiology of anti-
DNAs. The analogy remains compelling: the mouse
models of SLE such as MRL/lpr have two phases of au-
toantibody induction. The first phase is characterized by
polyclonal, unmutated IgM Abs (38) and appears to result
from nonspecific activation. The second phase is character-
ized by oligoclonal, IgG Abs and resembles a typical, Ag-
driven immune response. Members of clones have somatic
mutations that yield amino acids such as arginine and aspar-
agines that play a role in DNA–protein interaction (39).
cGVH in the anti-DNA site directed transgenic mice
also undergoes both types of activation. All B cells have in-
creased levels of activation markers in 3H9( ) after
cGVH, even though only a subset of B cells are anti-DNA
(20). A similar phenotype was found in preliminary data
from bm12→56( ) (excepting CD23). This indicates a
nonspecific activation phase (20). This study also shows
that the IgM B cells are highly diverse i.e., polyclonal.
Most, but not all, IgM hybridomas bind DNA, and the
anti-DNAs have different avidities. In addition, most of
these B cells are independently derived. Even though the
majority express the sd-tg and the V 38c L chain, they can
be shown to be of independent origin by several criteria:
they utilize different J  segments or they have unique V -
J  junctions. Within the entire subset of IgM anti-dsDNA
hybridomas, at most 4/18 (22%) might be clonally related
as compared with 8/11, or 73%, in the set of IgG anti-
DNA (see below).
That cGVH also causes an Ag-driven immune response
was first suggested by the narrow spectrum of the specifici-
ties of the IgG autoantibodies expressed in these mice (12,
13). If autoimmunity in GVH were entirely due to nonspe-
cific activation, then a much broader spectrum would be
expected and would include many other autoantibodies
seen in other murine models of autoimmunity. This is not
the case and instead just autoantibodies typical of SLE are
expressed. The transgenic models allows us to reach a simi-
lar conclusion: whereas nonspecific activation should yield
edited anti-DNAs or anti-ssDNA Abs, the majority of
monoclonal IgGs bind dsDNA. Serum anti-DNA titers also
show that anti-dsDNA increases disproportionately to anti-
ssDNA (Fig. 1). In sum, the restricted production of B cells
that recognize a single Ag and the bias toward anti-dsDNA
point toward a stage of Ag activation during cGVH.
Figure 5. Genealogical trees
generated from hybridoma se-
quences, demonstrating ongoing
somatic VH region diversifica-
tion (Hybridomas are those ana-
lyzed in Figs. 3 and 4). The indi-
vidual clones sequenced were
assigned to a particular genealog-
ical tree on the basis of shared
and unique VH mutations. Al-
though we interpret most shared
mutations as representing single
events, we did observe indepen-
dent parallel mutations (pre-
sumed hot spots). Multiple
hybridomas with identical nu-
cleotide sequences share a line.
The height of each line shows the number of mutations recorded. For clarity, the hybridomas are identified by number within the ovals. Note the high
number of mutations carried by each of the sequences analyzed. All hybrids except 169, 177, 2, and 107 bind dsDNA.T
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The IgG anti-DNAs have other properties of Ag-driven
immune responses, in that they are members of expanded
clones and are mutated. In our study of eleven randomly
selected IgG2a anti-dsDNAs, two sets had highly homolo-
gous VH and VH CDR3 regions, suggesting that each set
represents an expanded clone (Figs. 3 and 4). Additionally,
some mutations among members are shared, a property that
usually results from their accumulation during clonal ex-
pansion. Taken together, the homologous CDR3 se-
quences and the hierarchical pattern of shared mutations
provide strong evidence that members of these sets have
descended from a single B cell precursor. As discussed
above, the V gene usage and pattern of mutations indicate
that the IgG anti-DNA B cells were selected for and driven
by DNA.
Even though the sd-tg is associated with relatively high
affinity anti-DNAs, it appears to be excluded in the DNA-
driven phase of the 56R model. Although every B cell at
the initial stage of development inherits the 3H9/56R sd-
tg, none of the GVH induced IgGs are encoded by the sd-
tg. In the anti-dsDNA IgG subset, all cells used an up-
stream VH gene that replaced the sd-tg or a VH derived
from the untargeted allele. How these arise could be ex-
plained in three different ways (see Fig. 6):
(a) A leaky H-STOP control. It is thought that a func-
tional H chain, presumably in combination with surrogate
L chain, stops further rearrangement at the H locus. This
STOP signal explains why the majority of B cells are in-
completely rearranged (DJ) on the silent allele. Accord-
ingly, an H chain tg should prevent rearrangement on the
untargeted allele. Nevertheless, H chain rearrangement is
found in H chain transgenics, either at the untargeted allele
or in the form of VH replacement of the tg VH. The fre-
quency of such rearrangements varies; in the anti-DNA sd-
tgs LPS-activated B cells 2% (3H9), 14% (3H9/56R), and
38% (3H9/56R/76R) have one or the other form. The site
at which these secondary VH rearrangements occur could
be in the pro-B cell, because the sd-tg does not completely
stop rearrangement, or later because of editing. At least
some VH replacement must occur early because N addition
is found at the V-D-J junctions. Thus, the tg  B cells may
be selected from a subpopulation of B cells with a VH rep-
ertoire encoded by endogenous genes. Alternatively, TdT
could be reengaged in mature B cells under cGVH.
(b) Mutation correction. Endogenous VH genes may be
introduced after Ag selection of the 3H9/56R B cells. We
and others have noted that V gene replacement occurs dur-
ing clonal expansion. In the 3H9/V 8 MRL/lpr, L chain
rearrangement followed (and rescued) a nonsense-mutated
L chain (28). VH replacement is seen in expanded clones
from RA synovium (40). As noted above, the clones ob-
served in GVH-induced anti-DNAs have unusually high
frequencies of somatic mutations. The R:S of these muta-
tions in certain FRs is low, showing that many lethal muta-
tions have occurred during clonal expansion. Thus, it is
conceivable that inactivation of the sd-tg followed by re-
placement or rearrangement at the untargeted allele ex-
plains the shift to endogenous VH gene usage. This model
implies that rearrangement can be reinitiated after Ag-
selection. This may be special to those cells in a clone with
a lethal H or L chain mutation.
(c) Autoimmune V gene replacement. VH and/or VL
rearrangement may be induced in autoimmunity. In fact, it
has been reported that recombination activating gene levels
are unusually high in SLE (41). This would lead to “reedit-
ing.” The key distinction between editing and reediting is
the setting in which the secondary rearrangement occurs.
Editing refers to rearrangement that takes place in imma-
Figure 6. Models.T
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ture cells in the bone marrow. By contrast, reediting takes
place in mature peripheral cells, and is associated with Ag-
driven immune responses. In our bm12→56R fusion, a
clear distinction between peripheral subsets provided evi-
dence of reediting under cGVH. In the IgG cells, sec-
ondary H chain rearrangement occurred frequently (see
above), whereas among IgM cells, most of which used an
unmodified 3H9/56R H chain, it must have been rare. In
addition, the IgG clones displayed characteristics typical of
B cells that have undergone a secondary immune response,
as indicated by clonally related sequences (discussed above)
and a high frequency of somatic point mutations. In this
subset, oligoclonality and hypermutation, along with iso-
type switching, clearly associates secondary VH rearrang-
ment with Ag activation under cGVH, and indicates
reediting. The increased frequency of such H chain
rearrangement in anti-dsDNA IgG cells, and the fact that
the anti-dsDNA IgG subset has been implicated in SLE pa-
thology, implies that reediting during clonal expansion
could play a key role in disease development. The mecha-
nism of reediting is also more clearly established in light of
these data. Within the anti-dsDNA IgG subset, very few
cells derived from VH replacement in the sd-tg allele (see
clone 2). This can be explained by the high percentage of
such VH rearrangements that might result in nonfunctional
joints (42). Most interestingly, a high percentage of these
cells (80%) used the second allele. Along with the fact that
none of these cells expressed both alleles simultaneously,
this strongly suggests that most VH reeditings result in de-
activation of the first (here, the transgenic) allele. This in
turn enables the more efficacious classical rearrangement
process to occur at the untargeted allele.
Our data do not allow us to distinguish among these
models. The reediting model or the lethal mutation model
are appealing because they explain the shift from tg to en-
dogenous gene usage. If we assume that DNA selects and
drives anti-DNA B cells, then we would expect the re-
sponse to include, indeed to prefer, the tg  B cells. The al-
ternative explanation for the shift would mean that the sub-
population of cells arising because of a leaky STOP signal
has a selective advantage. Although this possibility may ap-
pear initially unlikely, further consideration of our se-
quence data could be supportive. The endogenous VH us-
age we found was highly restricted. This implies that
certain endogenous VH genes may have DNA binding
properties. In fact, most members of the anti-dsDNA IgG
clones sequenced used the J558.B3, J558.B4 genes. These
genes are unique to the B6 VH locus (30) and have
CDR1/CDR2 regions that are rich in asparagine residues.
These residues form a pocket of positive and negative
charges that should attract DNA/protein complexes. These
features suggest that B cells carrying H chains with in-
creased affinity for dsDNA may be preferentially selected
and expanded. Additionally, in the nearby FWR2 area of
these hybridomas, residues located between positions 24
and 30 sustained somatic mutations to arginine codons.
These arginines occupy the space adjacent to the previously
mentioned pocket of asparagine residues, suggesting that
these mutations actively increase the tendency of this re-
gion to bind dsDNA. The VH characteristics of these
clones strongly suggest a process of positive selection, with
DNA as the Ag.
This analysis prompts us to consider the role of strain-
specific loci in the development of disease (SLE susceptibil-
ity loci). These and other studies have shown that lupus au-
toantibodies may be determined by allotype-linked gene(s).
For example, [MRL/lpr (Ighj)   B6/lpr (Ighb)]F1 mice ex-
press SLE-Abs mainly of the b allotype (43). This bias is
borne out in our study. We found that most IgG2a anti-
dsDNA mAbs rescued in the bm12→56( ) were of the Ighb
allotype. These findings may provide clues to the cause of
this allotype dependence. In our mouse model, which pos-
sesses a diploid number of  150 VHJ558 (a and b), the VH
germline repertoire used by the anti-dsDNA IgG Abs does
not represent a random sample. Rather most (73%) of the
monoclonal anti-dsDNA Abs sequenced were encoded by
VH genes that shared the positively charged motif in the
CDR2 region. This region, not found in most other J558
VH, represents a highly restricted population. Therefore, in
this model, it is likely that the higher predisposition to form
anti-dsDNA B cells on a B6 background would be due to
availability of these VH germlines, and, specifically, that
differences such as charge between the b and a allotype V
regions would make the b-allotype more likely to bind
charged Ag, such as DNA.
In summary, then, we have identified two stages of acti-
vation during cGVH: a stage of nonspecific activation rep-
resented by the IgM subset, and a stage of Ag activation
represented by the IgG subset. In the former, allo-T cells
provided signals that stimulated most B cells nonspecifi-
cally. In the latter, Ag selected and expanded specific B cell
clones. The Ag is most likely dsDNA, as evidenced by the
selection of cells carrying a dense, positively charged region
in the CDR, and by arginine mutations proximate to this
area. The fact that all members of clone 1 bound only
DNA also makes it the likely driving molecule.
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